Suppr超能文献

超声引导下经皮注射凝血酶治疗导管术后假性动脉瘤

Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm.

作者信息

Kuma Sosei, Morisaki Koichi, Kodama Akio, Guntani Atsushi, Fukunaga Ryota, Soga Yoshimitsu, Shirai Shinichi, Ishida Masaru, Okazaki Jin, Mii Shinsuke

机构信息

Department of Vascular Surgery, Kokura Memorial Hospital.

出版信息

Circ J. 2015;79(6):1277-81. doi: 10.1253/circj.CJ-14-1119. Epub 2015 Mar 20.

Abstract

BACKGROUND

The efficacy and safety of ultrasound-guided thrombin injection (UGTI) for the treatment of post-catheterization femoral and brachial artery pseudoaneurysms (PSA) is unclear in Japan.

METHODS AND RESULTS

A retrospective study of 32 consecutive patients undergoing percutaneous UGTI of post-catheterization PSA between February 2011 and February 2014 was performed. There were 23 femoral PSA and 9 brachial PSA treated with UGTI. The prevalence of CAD and smoking history were higher in the brachial PSA patients, but there were no statistically significant differences in other patient demographic factors or in the preprocedural antiplatelet therapy between the femoral and brachial PSA patients. The median dose of thrombin injected was 200 U (range, 100-600 U). The initial success rate, early recurrence rate and surgical conversion rate were 91%, 0% and 4% in the femoral PSA, and 89%, 11% and 11% in the brachial PSA, respectively. There were 2 cases of medial nerve compression in the brachial PSA group, but there were no complications in the femoral PSA group (P=0.0198). On outpatient clinical follow-up in the successfully treated patients, there were no recurrences after an average follow-up of 16 months.

CONCLUSIONS

UGTI is a feasible, safe and effective less-invasive treatment for post-catheterization PSA. Brachial PSA, however, might require additional attention because of their tendency toward higher recurrence and complications.

摘要

背景

在日本,超声引导下注射凝血酶(UGTI)治疗导管插入术后股动脉和肱动脉假性动脉瘤(PSA)的有效性和安全性尚不清楚。

方法与结果

对2011年2月至2014年2月间连续32例行经皮UGTI治疗导管插入术后PSA的患者进行回顾性研究。其中23例为股动脉PSA,9例为肱动脉PSA接受了UGTI治疗。肱动脉PSA患者中冠心病患病率和吸烟史较高,但股动脉和肱动脉PSA患者在其他患者人口统计学因素或术前抗血小板治疗方面无统计学显著差异。注射凝血酶的中位剂量为200 U(范围100 - 600 U)。股动脉PSA的初始成功率、早期复发率和手术转换率分别为91%、0%和4%,肱动脉PSA分别为89%、11%和11%。肱动脉PSA组有2例正中神经受压,股动脉PSA组无并发症发生(P = 0.0198)。在成功治疗的患者门诊临床随访中,平均随访16个月后无复发。

结论

UGTI是治疗导管插入术后PSA一种可行、安全且有效的微创治疗方法。然而,肱动脉PSA可能因其较高的复发率和并发症倾向而需要额外关注。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验